Genmab A/S (GMAB) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.55
- Estimate
- $0.32
- Surprise
- +70.5%
- Revenue (period 2026-09-30)
- $1.19B
- Score at report (before → after)
- 5.4 → 5.2/10
Revenue source: yfinance_provisional (provisional — SEC XBRL not yet filed for this period).
How the report landed
Genmab A/S (GMAB) beat the $0.32 estimate with adjusted EPS of $0.55 — a large 70.5% upside surprise. TrendMatrix's engine moved from Hold (5.4/10) to Sell at 5.2/10 after the report — the engine's score fell despite the beat.
Coverage in the report window
- Genmab Q3 EPS $5.51 Beats $3.59 Estimate, Sales $1.187B Miss $1.194B Estimate — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates GMAB Sell at 5.5/10.
2 of the last 4 quarters beat the estimate; this quarter's +70.5% surprise compares with a +10.9% four-quarter average. Next scheduled report: 2027-02-16.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.8 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Thin upside margin: 5.4%
- Consecutive earnings misses (2)
- Earnings estimates trending DOWN
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $53.63
- Price target
- $56.52
- Stop
- $49.88
- Upside to target
- +5.4%
- Reward-to-risk
- 0.4:1
The stock trades at 45.8× trailing but 33.9× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 78 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
GMAB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $32.98B
- P/E (fwd)
- 33.9
- P/E (ttm)
- 45.8
- 52-week range
- $23.62–$59.97
- Off 52-week high
- 10.6%
- RSI (14)
- 78
- Volume vs avg
- 1.24×
- Score today
- 5.5/10